Back to News
Market Impact: 0.4
Biotech Stocks Rally: SLN Soars 125%, WORX Jumps 105%, IRON Gains 41%
Source: Nasdaq
Healthcare & BiotechM&A & Restructuring
Biotech and healthcare stocks surged Monday amid three developments: Silence Therapeutics’ $1.3 billion acquisition deal, a new healthcare agreement for SCWorx, and positive Phase 3 trial results for Disc Medicine. The article provides no deal terms, trial figures, or magnitude for the stock gains.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
IRON0.70
SLN0.70
More News
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Disc Medicine stock soars: take profit or buy into strength?
- BMO raises Disc Medicine stock price target on positive trial data
- Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany